Table 2 Clinical activity indices for ulcerative colitis. Statistical comparison between invasive and noninvasive indices showed that endoscopy ... The clinical features of toxic megacolon are ...

With over 250 peer-reviewed publications, he has made significant contributions to medical literature, shedding light on the treatment and understanding of ulcerative colitis and Crohn's disease.

However, endoscopy with biopsy is often essential ... The two types of IBD are: Ulcerative colitis (UC): affects the large intestine and rectum Crohn’s disease: can affect any part of the ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Additionally, species-level data from two landmark FMT trials (the Transplantation of Feces in Ulcerative Colitis; Returning Nature's Homeostasis [TURN] and Fecal Microbiota Transplantation for ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Ulcerative colitis (UC) is an inflammatory bowel disease ... The researchers analyzed the clinical, endoscopic, and tissue data of 220 patients with UC who underwent treatment and successfully ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key ...

today announced positive topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC). This press release features multimedia.